Feasibility and Acute Toxicity of Hypo-Fractionated Radiotherapy on 0.35T MR-LINAC: The First Prospective Study in Spain

This observational, descriptive, longitudinal, and prospective basket-type study (Registry #5289) prospectively evaluated the feasibility and acute toxicity of hypo-fractionated radiotherapy on the first 0.35T MR-LINAC in Spain. A total of 37 patients were included between August and December 2023,...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-05, Vol.16 (9), p.1685
Main Authors: Gonsalves, Daniela, Ocanto, Abrahams, Meilan, Eduardo, Gomez, Alberto, Dominguez, Jesus, Torres, Lisselott, Pascual, Castalia Fernández, Teja, Macarena, Linde, Miguel Montijano, Guijarro, Marcos, Rivas, Daniel, Begara, Jose, González, Jose Antonio, Andreescu, Jon, Holgado, Esther, Alcaraz, Diego, López, Escarlata, Dzhugashvli, Maia, Lopez-Campos, Fernando, Alongi, Filippo, Couñago, Felipe
Format: Article
Language:English
Subjects:
Abdomen
Acute toxicity
Adaptation
Boolean
Cancer therapies
Care and treatment
Cystitis
Feasibility studies
Localization
Magnetic resonance imaging
Optimization
Pancreatic cancer
Patients
Planning
Prostate cancer
Quality assurance
Quality control
Radiation therapy
Radiotherapy
Simulation
Tomography
Toxicity
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This observational, descriptive, longitudinal, and prospective basket-type study (Registry #5289) prospectively evaluated the feasibility and acute toxicity of hypo-fractionated radiotherapy on the first 0.35T MR-LINAC in Spain. A total of 37 patients were included between August and December 2023, primarily with prostate tumors (59.46%), followed by pancreatic tumors (32.44%). Treatment regimens typically involved extreme hypo-fractionated radiotherapy, with precise dose delivery verified through quality assurance measures. Acute toxicity assessment at treatment completion revealed manageable cystitis, with one case persisting at the three-month follow-up. Gastrointestinal toxicity was minimal. For pancreatic tumors, daily adaptation of organ-at-risk (OAR) and gross tumor volume (GTV) was practiced, with median doses to OAR within acceptable limits. Three patients experienced gastrointestinal toxicity, mainly nausea. Overall, the study demonstrates the feasibility and safety of extreme hypo-fractionated radiotherapy on a 0.35T MR-LINAC, especially for challenging anatomical sites like prostate and pancreatic tumors. These findings support the feasibility of MR-LINAC-based radiotherapy in delivering precise treatments with minimal toxicity, highlighting its potential for optimizing cancer treatment strategies.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16091685